AU2003227687B2 - Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein - Google Patents

Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein Download PDF

Info

Publication number
AU2003227687B2
AU2003227687B2 AU2003227687A AU2003227687A AU2003227687B2 AU 2003227687 B2 AU2003227687 B2 AU 2003227687B2 AU 2003227687 A AU2003227687 A AU 2003227687A AU 2003227687 A AU2003227687 A AU 2003227687A AU 2003227687 B2 AU2003227687 B2 AU 2003227687B2
Authority
AU
Australia
Prior art keywords
factor
lrp
factor viii
seq
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003227687A
Other languages
English (en)
Other versions
AU2003227687A1 (en
Inventor
Arend Niels Bovenschen
Koenraad Mertens
Manfred Rieger
Friedrich Scheiflinger
Jan Voorberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanquin
Original Assignee
Sanquin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin filed Critical Sanquin
Publication of AU2003227687A1 publication Critical patent/AU2003227687A1/en
Assigned to STICHTING SANQUIN BLOEDVOORZIENING reassignment STICHTING SANQUIN BLOEDVOORZIENING Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC., STICHTING SANQUIN BLOEDVOORZIENING
Application granted granted Critical
Publication of AU2003227687B2 publication Critical patent/AU2003227687B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003227687A 2002-04-29 2003-04-28 Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein Ceased AU2003227687B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29
US60/376,351 2002-04-29
PCT/EP2003/004425 WO2003093313A2 (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein

Publications (2)

Publication Number Publication Date
AU2003227687A1 AU2003227687A1 (en) 2003-11-17
AU2003227687B2 true AU2003227687B2 (en) 2009-10-15

Family

ID=29401334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003227687A Ceased AU2003227687B2 (en) 2002-04-29 2003-04-28 Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein

Country Status (10)

Country Link
US (1) US8586538B2 (enExample)
EP (1) EP1497330B1 (enExample)
JP (2) JP2005535588A (enExample)
AT (1) ATE463514T1 (enExample)
AU (1) AU2003227687B2 (enExample)
CA (1) CA2484155C (enExample)
DE (1) DE60332011D1 (enExample)
DK (1) DK1497330T3 (enExample)
ES (1) ES2343681T3 (enExample)
WO (1) WO2003093313A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP5674650B2 (ja) * 2008-06-04 2015-02-25 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
JP5394864B2 (ja) * 2009-09-10 2014-01-22 アスモ株式会社 モータ
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041816A1 (en) * 1995-06-12 1996-12-27 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation
WO2000028021A1 (de) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Ein faktor viii-polypeptid mit faktor viii:c-aktivität

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760678B2 (en) * 1998-05-08 2003-05-22 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041816A1 (en) * 1995-06-12 1996-12-27 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation
WO2000028021A1 (de) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Ein faktor viii-polypeptid mit faktor viii:c-aktivität

Also Published As

Publication number Publication date
CA2484155A1 (en) 2003-11-13
JP2010202664A (ja) 2010-09-16
US20080219983A1 (en) 2008-09-11
CA2484155C (en) 2015-10-13
ATE463514T1 (de) 2010-04-15
EP1497330B1 (en) 2010-04-07
WO2003093313A3 (en) 2004-07-29
WO2003093313A2 (en) 2003-11-13
DK1497330T3 (da) 2010-06-14
EP1497330A2 (en) 2005-01-19
AU2003227687A1 (en) 2003-11-17
ES2343681T3 (es) 2010-08-06
JP2005535588A (ja) 2005-11-24
DE60332011D1 (de) 2010-05-20
US8586538B2 (en) 2013-11-19

Similar Documents

Publication Publication Date Title
US8586538B2 (en) Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
JP6527918B2 (ja) 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
JP6336522B2 (ja) 細胞取込みが低下した第ｖｉｉｉ因子変異体
US8546332B2 (en) Factor VIII polypeptide having factor VIII:C activity
KR101841870B1 (ko) 표적화 응고 인자 및 그의 사용 방법
EP2796145B1 (en) A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
US20220213200A1 (en) Anti-gpiib/iiia antibodies or uses thereof
RS66972B1 (sr) Metode lečenja hemofilije a
WO2015070014A1 (en) Procoagulant fusion compound
Chavin et al. The Purification, Structure, and Function of Factor VIII
WO2018037217A1 (en) Clotting factor
WO2001058475A1 (en) Regulation of platelet adhesion and aggregation
US20030040515A1 (en) Regulation of platelet adhesion and aggregation
HK1203409B (en) A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NZ619438A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: STICHTING SANQUIN BLOEDVOORZIENING

Free format text: FORMER APPLICANT(S): STICHTING SANQUIN BLOEDVOORZIENING; BAXTER HEALTHCARE S.A.; BAXTER INTERNATIONAL INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired